PerkinElmer, Inc. (NYSE:PKI) has been assigned an average rating of “Hold” from the sixteen research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $77.83.

Several equities analysts have recently weighed in on the company. Barclays raised their target price on PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a research report on Friday, January 26th. Robert W. Baird restated a “buy” rating and issued a $88.00 target price on shares of PerkinElmer in a research report on Friday, January 26th. Cowen restated a “hold” rating and issued a $84.00 target price on shares of PerkinElmer in a research report on Friday, January 26th. ValuEngine downgraded PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Morgan Stanley raised their target price on PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a research report on Friday, November 3rd.

PerkinElmer (PKI) traded down $0.38 during midday trading on Friday, hitting $74.12. The stock had a trading volume of 205,999 shares, compared to its average volume of 756,321. The stock has a market capitalization of $8,027.70, a P/E ratio of 24.94, a PEG ratio of 1.68 and a beta of 0.76. PerkinElmer has a 1-year low of $53.97 and a 1-year high of $84.49. The company has a debt-to-equity ratio of 0.72, a quick ratio of 0.90 and a current ratio of 1.27.

PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.03. The business had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. PerkinElmer had a return on equity of 13.30% and a net margin of 12.97%. The business’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.83 earnings per share. research analysts forecast that PerkinElmer will post 3.52 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be issued a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $0.28 annualized dividend and a dividend yield of 0.38%. PerkinElmer’s dividend payout ratio is presently 10.61%.

In related news, Director Alexis P. Michas sold 5,000 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $73.18, for a total value of $365,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Frank Anders Wilson sold 37,535 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $70.14, for a total value of $2,632,704.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 59,812 shares of company stock valued at $4,263,863. Insiders own 2.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Cutler Group LP increased its stake in PerkinElmer by 845.7% during the fourth quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock worth $163,000 after acquiring an additional 2,537 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in PerkinElmer by 53.8% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock worth $170,000 after acquiring an additional 779 shares during the last quarter. Waldron LP acquired a new stake in PerkinElmer during the third quarter worth $200,000. Seaward Management Limited Partnership acquired a new stake in PerkinElmer during the third quarter worth $202,000. Finally, Signition LP acquired a new stake in PerkinElmer during the fourth quarter worth $207,000. 90.41% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://theolympiareport.com/2018/02/13/brokerages-set-perkinelmer-inc-pki-pt-at-77-83.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.